低分子肝素联合依达拉奉治疗进展性脑梗死的效果观察

目的探讨低分子肝素联合依达拉奉治疗进展性脑梗死的临床效果。方法将本院2010年9月～2012年12月收治的90例进展性脑梗死患者分为对照组与观察组,每组各45例,对照组患者给予基础治疗和低分子肝素治疗,观察组患者在对照组的基础上给予依达拉奉治疗,观察两组患者的临床疗效和神经功能缺损评分。结果对照组患者的总有效率为77.8%,明显低于观察组的88.9%,两组间比较,差异有统计学意义（P〈0.05）。观察组与对照组患者治疗后1、2周时,神经功能缺损评分明显降低,观察组降低水平高于对照组,治疗1、2周时,两组间比较,差异有统计学意义（P〈0.05）。结论依达拉奉联合低分子肝素治疗进展性脑梗死效果显著,值得临床推广应用。

Effect of observation on low molecular heparin combined with edaravone in treatment of progressive cerebral infarction

Objective To explore the clinical effect of low molecular heparin combined with edaravone in treatment of progressive cerebral infarction. Methods Ninety patients with progressive cerebral infarction were divided into control group and observation group in our hospital in September 2010 to December 2012, 45 cases in each group, the control group with low molecular heparin therapy, treatment and observation group on base of the control group was given edaravone treated, the clinical efficacy and neural function defect score of two groups of patients were observe. Results The total effective rate was 77.8% in control group, it was significantly lower than the 88.9% in observation group, the difference was statistically significant between the two groups （P 0.05）. At 1, 2 weeks after treatment between the observation group and control group, the neural function defect score significantly lower, the lower level in observation group was greater than the control group, the difference was statistically significant between the two groups after treatment 1, 2 weeks （P 0.05）. Conclusion Edaravone combined with low molecular heparin in treatment of progressive cerebral infarction have the significant effect, it is worthy of clinical popularization and application.